WO1999041411A3 - Method for diagnosis and treatment of disorders of carbohydrate metabolism - Google Patents
Method for diagnosis and treatment of disorders of carbohydrate metabolism Download PDFInfo
- Publication number
- WO1999041411A3 WO1999041411A3 PCT/SE1999/000177 SE9900177W WO9941411A3 WO 1999041411 A3 WO1999041411 A3 WO 1999041411A3 SE 9900177 W SE9900177 W SE 9900177W WO 9941411 A3 WO9941411 A3 WO 9941411A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- promoter
- carbohydrate metabolism
- patient
- adenylate cyclase
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000531591A JP2002503483A (en) | 1998-02-11 | 1999-02-11 | Methods of diagnosing and treating glucose metabolism disorders |
AU26512/99A AU2651299A (en) | 1998-02-11 | 1999-02-11 | Method for diagnosis and treatment of disorders of carbohydrate metabolism |
EP99906659A EP1053356A2 (en) | 1998-02-11 | 1999-02-11 | Method for diagnosis and treatment of disorders of carbohydrate metabolism |
CA002319065A CA2319065A1 (en) | 1998-02-11 | 1999-02-11 | Method for diagnosis and treatment of disorders of carbohydrate metabolism |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7442798P | 1998-02-11 | 1998-02-11 | |
US60/074,427 | 1998-02-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999041411A2 WO1999041411A2 (en) | 1999-08-19 |
WO1999041411A3 true WO1999041411A3 (en) | 1999-09-30 |
Family
ID=22119512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1999/000177 WO1999041411A2 (en) | 1998-02-11 | 1999-02-11 | Method for diagnosis and treatment of disorders of carbohydrate metabolism |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1053356A2 (en) |
JP (1) | JP2002503483A (en) |
AU (1) | AU2651299A (en) |
CA (1) | CA2319065A1 (en) |
WO (1) | WO1999041411A2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994014427A2 (en) * | 1992-12-23 | 1994-07-07 | Zymogenetics, Inc. | Use of skyrin and analogues for the treatment of diabetes mellitus and process for their preparation |
WO1996036641A1 (en) * | 1995-05-19 | 1996-11-21 | The Johns Hopkins University School Of Medicine | Susceptibility gene for obesity and type ii diabetes mellitus |
WO1997004331A1 (en) * | 1995-07-20 | 1997-02-06 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | System and method for performing in vivo imaging and oxymetry and ft microscopy by pulsed radiofrequency electron paramagnetic resonance |
-
1999
- 1999-02-11 EP EP99906659A patent/EP1053356A2/en not_active Withdrawn
- 1999-02-11 AU AU26512/99A patent/AU2651299A/en not_active Abandoned
- 1999-02-11 CA CA002319065A patent/CA2319065A1/en not_active Abandoned
- 1999-02-11 JP JP2000531591A patent/JP2002503483A/en active Pending
- 1999-02-11 WO PCT/SE1999/000177 patent/WO1999041411A2/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994014427A2 (en) * | 1992-12-23 | 1994-07-07 | Zymogenetics, Inc. | Use of skyrin and analogues for the treatment of diabetes mellitus and process for their preparation |
WO1996036641A1 (en) * | 1995-05-19 | 1996-11-21 | The Johns Hopkins University School Of Medicine | Susceptibility gene for obesity and type ii diabetes mellitus |
WO1997004331A1 (en) * | 1995-07-20 | 1997-02-06 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | System and method for performing in vivo imaging and oxymetry and ft microscopy by pulsed radiofrequency electron paramagnetic resonance |
Non-Patent Citations (1)
Title |
---|
ABDEL-HALIM S ET AL: "Mutations in the promoter of adenyl cyclase (AC)-III gene, overexpression of AC-III mRNA, and enhanced cAMP generation in Islets from the spontaneously diabetic GK RAT Model of Type 2 Diabetes", DIABETES, vol. 47, no. 3, March 1998 (1998-03-01), pages 498 - 504, XP002110194 * |
Also Published As
Publication number | Publication date |
---|---|
AU2651299A (en) | 1999-08-30 |
WO1999041411A2 (en) | 1999-08-19 |
EP1053356A2 (en) | 2000-11-22 |
JP2002503483A (en) | 2002-02-05 |
CA2319065A1 (en) | 1999-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Van Dop et al. | ADP-ribosylation of transducin by pertussis toxin blocks the light-stimulated hydrolysis of GTP and cGMP in retinal photoreceptors. | |
Diamond | Phenylalanine levels of 6‐10mg/dl may not be as benign as once thought | |
Rada et al. | Galanin in the hypothalamus raises dopamine and lowers acetylcholine release in the nucleus accumbens: a possible mechanism for hypothalamic initiation of feeding behavior | |
EP0788307A4 (en) | Oligonucleotide modulation of multidrug resistance-associated protein | |
WO2005027839A3 (en) | Methods and reagents for the treatment of immunoinflammatory disorders | |
Engel et al. | Laminar difference in GABA uptake and GAT-1 expression in rat CA1 | |
WO2005037203A3 (en) | Methods and reagents for the treatment of immunoinflammatory disorders | |
WO2003078658A3 (en) | Methods for diagnosing and treating schizophrenia | |
WO2000038666A3 (en) | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | |
WO2002097033A3 (en) | Antibodies that immunospecifically bind to trail receptors | |
Ohi et al. | Cadmium-induced accumulation of metallothionein messenger RNA in rat liver. | |
Yasoshima et al. | Rat gustatory memory requires protein kinase C activity in the amygdala and cortical gustatory area | |
WO2001000661A3 (en) | Carnitine carrier related protein-1 | |
WO2003085093A3 (en) | Antibodies that specifically bind to gmad | |
EP1609856A3 (en) | Brain or heart cyclic nucleotide gated ion channel compounds and uses thereof | |
ATE206875T1 (en) | METHOD OF IMPROVING THE REPRODUCTIVE ABILITY OF BOARS BY USING A SPECIAL FEED FOR BREEDING BOARS | |
Fazan Jr et al. | Sildenafil acts on the central nervous system increasing sympathetic activity | |
Mundinger et al. | Short-term diabetic hyperglycemia suppresses celiac ganglia neurotransmission, thereby impairing sympathetically mediated glucagon responses | |
ATE162721T1 (en) | NEW PROBE FOR TUMOR DIAGNOSTICS OR TUMOR THERAPY | |
WO1999041411A3 (en) | Method for diagnosis and treatment of disorders of carbohydrate metabolism | |
Ksir et al. | Enhanced behavioral response to nicotine in an animal model of Alzheimer's disease | |
Ninomiya et al. | Enhanced responses of the chorda tympani nerve to nonsugar sweeteners in the diabetic db/db mouse | |
Fleming et al. | Pertussis toxin-treated dog: a whole animal model of impaired inhibitory regulation of adenylate cyclase. | |
Grass et al. | Reduced spinal cord sensitization to C‐fibre stimulation in mice over‐expressing galanin | |
WO2005018536A3 (en) | Agonist antibodies that specifically bind the glucagon like peptide-1 receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2319065 Country of ref document: CA Ref country code: CA Ref document number: 2319065 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999906659 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09600378 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999906659 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999906659 Country of ref document: EP |